Peptide quality is often reduced to a single purity percentage, but that number answers only one narrow question. Real quality depends on identity, purity, content, contaminants, stability and the manufacturing system behind a batch. Below are eight widespread misconceptions, why they are wrong, and what the evidence actually says.
Key Takeaways
- HPLC purity is not the same as the amount of peptide in a sample [1].
- Purity testing does not confirm identity, and a mass match does not confirm purity [1].
- A high purity result says nothing about endotoxin or sterility [2].
- Counter-ions like trifluoroacetate (TFA) can affect experiments [3].
- A Certificate of Analysis describes tested samples, not a guarantee for every unit [4].
Misconception 1: "99% pure means the vial is 99% peptide"
This is the most common mix-up. HPLC purity compares the main peak with other peaks detected in the chromatogram. It is a relative measure of peptide-related components.
A peptide powder also contains other material that HPLC purity does not count:
- Counter-ions such as acetate, trifluoroacetate or chloride, which pair with charged groups on the peptide [1].
- Water, because peptides are often very hygroscopic (they absorb moisture from the air) [1].
- Residual solvents from manufacturing [1].
So a sample can have excellent HPLC purity yet contain noticeably less peptide by weight. That is why regulators treat assay (content) as a separate test from purity, measured by methods such as chromatography against a reference standard, amino acid analysis, nitrogen analysis or quantitative NMR [1]. Our guide to identity vs. purity vs. quantity testing explains the difference.
Misconception 2: "A purity result proves it's the right peptide"
An HPLC trace shows how many components there are and in what proportions. It does not, by itself, prove that the main peak is the intended molecule. That requires identity testing. The European Medicines Agency recommends at least two orthogonal methods (independent techniques based on different principles) to identify a synthetic peptide, such as mass, relative retention time, LC-MS, peptide mapping, amino acid analysis or NMR [1]. (This is an EU guideline for medicines, applicable since 1 June 2026; other jurisdictions set their own requirements.)
Misconception 3: "A mass spec match means the sample is pure and correct"
The reverse mistake is just as common. Mass spectrometry confirms that a molecule of the expected mass is present. But:
- It does not tell you how much of the sample is that molecule.
- Some impurities have the same mass as the intended peptide. For example, isomerisation and racemisation (conversion of an amino acid into its mirror-image form) change a peptide's structure without changing its mass [5]. The EMA notes that controlling such diastereomers may require specific methods [1].
Mass confirms identity at one level; it is not a full quality assessment.
Misconception 4: "One clean peak means one compound"
Chromatography separates compounds by how they interact with the column, but structurally similar impurities can co-elute, meaning they come out together and appear as a single peak. The EMA specifically warns about the risk of co-eluting impurities in peptides, says additional independent methods may be needed, and states that when co-eluting impurities appear as one peak, the 1.0% qualification threshold applies unless otherwise justified [1]. A single sharp peak is encouraging, but it is not proof of a single compound.
Misconception 5: "High purity means it's clean and sterile"
HPLC purity measures peptide-related components. It is not designed to detect bacterial endotoxins or living microorganisms. These require separate tests (see endotoxin and sterility testing).
A 2024 study shows why this matters. Researchers analysed semaglutide vials bought from illegal online sellers. No viable microorganisms were found at the time of testing, but endotoxin was detected in every sample, and measured purity was far below the 99% claimed on the labels [2]. A separate Belgian study of falsified peptide drugs from suspected illegal online pharmacies found toxic elemental impurities, including arsenic and lead, in some samples [6]. Neither kind of contaminant would show up as a purity percentage.
Misconception 6: "Counter-ions are just filler and don't matter"
Counter-ions are part of what you are weighing, and they can have their own biological effects. Peptides purified by reversed-phase HPLC are often isolated as trifluoroacetate (TFA) salts. In a study from the University of Auckland, TFA at very low concentrations reduced the growth of bone and cartilage cells in culture. When the TFA and hydrochloride salts of the same peptides were compared, the TFA salts consistently showed less cell growth, which could lead researchers to miss a real effect or wrongly attribute an inhibitory effect to the peptide [3].
The EMA's guideline states that the type of counter-ion can affect a peptide's biological and physicochemical properties, and that the counter-ion should be defined and its amount controlled with a justified limit [1].
Misconception 7: "Freeze-dried peptides don't degrade"
Freeze-drying (lyophilization) usually makes peptides much more stable than they are in solution, but it does not stop degradation entirely. A major review of solid protein pharmaceuticals notes that even after successful lyophilization, proteins in the solid state may still have limited long-term storage stability [7]. The EMA notes that peptides are generally stored refrigerated or frozen to prevent or minimise degradation, and that water content should be monitored for hygroscopic powders [1]. See how peptides degrade for the chemistry.
Misconception 8: "A Certificate of Analysis guarantees every vial"
A Certificate of Analysis (COA) reports results for the samples tested from a batch. It cannot directly prove the quality of every unit. The FDA explains that testing is usually done on a small sample of a batch, which is why quality has to be built into manufacturing through Current Good Manufacturing Practice, rather than relying on testing alone [4]. A COA is also only as trustworthy as the laboratory that produced it and its link to the specific batch.
Quick Reference: Misconception vs. Reality
| Misconception | Reality | What answers the real question |
|---|---|---|
| 99% pure = 99% peptide | Purity is relative; powder also holds water, salts, solvents | Content / assay test [1] |
| Purity proves identity | Purity shows proportions, not which molecule | Two or more orthogonal identity methods [1] |
| Mass match = pure | Same-mass impurities exist | HPLC purity plus specific methods [1][5] |
| One peak = one compound | Impurities can co-elute | Additional separation methods [1] |
| Pure = sterile | Purity tests don't detect endotoxin or microbes | Endotoxin and sterility tests [2] |
| Counter-ions don't matter | TFA can affect cell experiments | Counter-ion content test [1][3] |
| Freeze-dried lasts forever | Solid-state degradation still occurs | Stability data, proper storage [1][7] |
| COA guarantees every vial | COA covers tested samples | GMP manufacturing system [4] |
The Bigger Picture on Peptide Quality
Most of these misconceptions come from treating one test as if it answered every question. Good quality assessment combines several tests with a controlled manufacturing process. That is the essential difference explored in our article on research-grade vs. pharmaceutical-grade.
Frequently Asked Questions
What is the difference between peptide purity and peptide content?
Purity is the proportion of the target peptide among peptide-related components detected by HPLC. Content is the actual amount of peptide in the powder by weight, after accounting for water, counter-ions and other non-peptide material [1].
Why do peptides contain TFA?
Trifluoroacetic acid is commonly used in reversed-phase HPLC purification, so purified peptides are often isolated as TFA salts [3]. Some are converted to other salt forms, such as acetate or hydrochloride.
Is a higher purity always better?
Higher purity generally means fewer peptide-related impurities, but it does not guarantee correct identity, adequate content, or absence of contaminants such as endotoxin. The type and amount of individual impurities also matter [1].
Can I trust a Certificate of Analysis?
A COA is useful evidence, especially if it comes from an identifiable, accredited lab, matches the batch, and includes raw data such as chromatograms. But it describes tested samples, not every unit [4].
Does "lab-tested" mean a product is safe?
No. Analytical testing describes the chemical quality of samples. Safety and effectiveness in people are established through clinical research and regulatory review.
References
- European Medicines Agency. Guideline on the Development and Manufacture of Synthetic Peptides (EMA/CHMP/CVMP/QWP/367182/2025). https://www.ema.europa.eu/en/development-manufacture-synthetic-peptides-scientific-guideline ↗
- Ashraf AR, Mackey TK, Vida RG, et al. Multifactor quality and safety analysis of semaglutide products sold by online sellers without a prescription. J Med Internet Res. 2024;26:e65440. https://doi.org/10.2196/65440 ↗
- Cornish J, Callon KE, Lin CQ, et al. Trifluoroacetate, a contaminant in purified proteins, inhibits proliferation of osteoblasts and chondrocytes. Am J Physiol. 1999;277(5):E779-E783. https://doi.org/10.1152/ajpendo.1999.277.5.E779 ↗
- U.S. Food and Drug Administration. Facts About the Current Good Manufacturing Practice (CGMP). https://www.fda.gov/drugs/pharmaceutical-quality-resources/facts-about-current-good-manufacturing-practice-cgmp ↗
- Geiger T, Clarke S. Deamidation, isomerization, and racemization at asparaginyl and aspartyl residues in peptides. J Biol Chem. 1987;262(2):785-794. https://pubmed.ncbi.nlm.nih.gov/3805008/ ↗
- Janvier S, Cheyns K, Canfyn M, et al. Impurity profiling of the most frequently encountered falsified polypeptide drugs on the Belgian market. Talanta. 2018;188:795-807. https://doi.org/10.1016/j.talanta.2018.06.023 ↗
- Wang W. Lyophilization and development of solid protein pharmaceuticals. Int J Pharm. 2000;203(1-2):1-60. https://doi.org/10.1016/s0378-5173(00)00423-3 ↗
This article is for educational purposes only and is not medical advice. For health decisions, consult a qualified healthcare professional, and for regulatory questions, consult the medicines regulator in your jurisdiction.